2134602-44-9

Product Details:

CasNo： 2134602-44-9

Molecular Formula： C19H18BrCl2N3O

Appearance： White to off-white Powder

Packing： Bottle

Throughput： 100KG/Month

Purity： 99%

CAS‑No：2134602‑44‑9

Compound type：G‑protein‑biased mu‑opioid receptor (MOR) partial agonist, successor / replacement of SR‑17018PMC

Product Description

SR15099 is a novel investigational small‑molecule mu‑opioid receptor partial agonist with G‑protein signaling bias. It serves as a functional replacement for SR‑17018 for research‑related applicationsPMC.

It preferentially activates G‑protein‑mediated signaling pathways at the mu‑opioid receptor, while exhibiting reduced β‑arrestin‑2 recruitment. This pharmacological profile is studied for potential separation of analgesic effects from typical opioid‑related adverse events such as respiratory depression, constipation and tolerance in pre‑clinical research models.

SR15099 is supplied as research‑grade material, typical purity ≥98%. It is intended exclusively for in‑vitro and pre‑clinical laboratory research use only, not for human diagnostic or therapeutic administration.

Indications (Research‑only, no clinical approved indication)

Important note: SR15099 has no FDA / EMA approved clinical indications. All below are pre‑clinical research objectives only.

1. Pre‑clinical research into novel analgesic agents targeting mu‑opioid receptor.
2. Pharmacology study of G‑protein biased opioid receptor signaling pathway.
3. Comparative pharmacological evaluation against SR‑17018 and other MOR agonists.
4. Animal model research for pain management, opioid tolerance and dependence mechanism studiesPMC.